CCCC vs. ALEC, CGEN, NRIX, NMRA, DNA, VIR, CGEM, TARS, FDMT, and BCRX
Should you be buying C4 Therapeutics stock or one of its competitors? The main competitors of C4 Therapeutics include Alector (ALEC), Compugen (CGEN), Nurix Therapeutics (NRIX), Neumora Therapeutics (NMRA), Ginkgo Bioworks (DNA), Vir Biotechnology (VIR), Cullinan Therapeutics (CGEM), Tarsus Pharmaceuticals (TARS), 4D Molecular Therapeutics (FDMT), and BioCryst Pharmaceuticals (BCRX). These companies are all part of the "medical" sector.
Alector (NASDAQ:ALEC) and C4 Therapeutics (NASDAQ:CCCC) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their media sentiment, institutional ownership, risk, earnings, profitability, community ranking, dividends, valuation and analyst recommendations.
Alector received 121 more outperform votes than C4 Therapeutics when rated by MarketBeat users. Likewise, 60.58% of users gave Alector an outperform vote while only 37.88% of users gave C4 Therapeutics an outperform vote.
Alector has higher revenue and earnings than C4 Therapeutics. Alector is trading at a lower price-to-earnings ratio than C4 Therapeutics, indicating that it is currently the more affordable of the two stocks.
Alector presently has a consensus price target of $14.00, suggesting a potential upside of 184.55%. C4 Therapeutics has a consensus price target of $10.13, suggesting a potential upside of 102.50%. Given C4 Therapeutics' stronger consensus rating and higher probable upside, equities analysts plainly believe Alector is more favorable than C4 Therapeutics.
In the previous week, C4 Therapeutics had 2 more articles in the media than Alector. MarketBeat recorded 3 mentions for C4 Therapeutics and 1 mentions for Alector. C4 Therapeutics' average media sentiment score of 1.87 beat Alector's score of 0.93 indicating that Alector is being referred to more favorably in the media.
85.8% of Alector shares are owned by institutional investors. Comparatively, 78.8% of C4 Therapeutics shares are owned by institutional investors. 9.1% of Alector shares are owned by company insiders. Comparatively, 8.0% of C4 Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.
Alector has a beta of 0.82, suggesting that its share price is 18% less volatile than the S&P 500. Comparatively, C4 Therapeutics has a beta of 3.22, suggesting that its share price is 222% more volatile than the S&P 500.
Alector has a net margin of -125.11% compared to Alector's net margin of -629.24%. Alector's return on equity of -52.85% beat C4 Therapeutics' return on equity.
Summary
Alector beats C4 Therapeutics on 13 of the 18 factors compared between the two stocks.
Get C4 Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for CCCC and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding CCCC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
C4 Therapeutics Competitors List
Related Companies and Tools
